LISATA THERAPEUTICS, INC.
LSTANext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for LSTA. That does not mean none is planned.
Get an email about LSTA's next catalysts
Track LISATA THERAPEUTICS (LSTA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 0 past
LSTA Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | FQ end Sep/2026 | Call: tbd
How LSTA's past catalysts played out
Market Overview
Stock performance and key metrics
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
WebsiteAuto-CD34+ cells
Chronic Myocardial Ischemia
therapeutic autologous dendritic cells
Melanoma (Skin)
CLBS16
Coronary Microvascular Dysfunction
NBS10
ST Segment Elevation Myocardial Infarction
CLBS14 (low-dose)
Myocardial Ischemia
CLBS03 Low Dose
Diabetes Mellitus
certepetide
Cholangiocarcinoma
CLBS03 High Dose
Diabetes Mellitus
CLBS14 (high-dose)
Myocardial Ischemia
CLBS12
Critical Limb Ischemia
SOC
Critical Limb Ischemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Auto-CD34+ cells | Phase 3 | Chronic Myocardial Ischemia | - | - |
therapeutic autologous dendritic cells | Phase 2 | Melanoma (Skin) | - | - |
CLBS16 | Phase 2 | Coronary Microvascular Dysfunction | - | - |
NBS10 | Phase 2 | ST Segment Elevation Myocardial Infarction | - | - |
CLBS14 (low-dose) | Phase 2 | Myocardial Ischemia | - | - |
CLBS03 Low Dose | Phase 2 | Diabetes Mellitus | - | - |
certepetide | Phase 2 | Cholangiocarcinoma | - | - |
CLBS03 High Dose | Phase 2 | Diabetes Mellitus | - | - |
CLBS14 (high-dose) | Phase 2 | Myocardial Ischemia | - | - |
CLBS12 | Phase 2 | Critical Limb Ischemia | - | - |
SOC | Phase 2 | Critical Limb Ischemia | - | - |
Critical Limb Ischemia
1 drug in this indication
Coronary Microvascular Dysfunction
1 drug in this indication
ST Segment Elevation Myocardial Infarction
1 drug in this indication
Cholangiocarcinoma
1 drug in this indication
Myocardial Ischemia
1 drug in this indication
Diabetes Mellitus
1 drug in this indication
Melanoma (Skin)
1 drug in this indication
Chronic Myocardial Ischemia
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in LISATA THERAPEUTICS, INC.'s drug pipeline?→
CatalystAlert tracks 11 drug candidates in LISATA THERAPEUTICS, INC.'s (LSTA) pipeline across Phase 3, Phase 2. Its lead program is Auto-CD34+ cells (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is LISATA THERAPEUTICS, INC.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for LISATA THERAPEUTICS, INC. (LSTA) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track LSTA biotech catalysts?→
Add LSTA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow LISATA THERAPEUTICS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.